Jaguar Health, Inc. (NASDAQ: JAGX) received formal notice from The Nasdaq Stock Market LLC on May 26, 2026, confirming the company has regained compliance with Nasdaq Listing Rule 5550(a)(2), according to a company statement.

The bid price rule requires listed companies to maintain minimum stock price levels. Jaguar's securities continue to be listed and traded on Nasdaq following the compliance notification.

"We are very happy that Jaguar has regained compliance with the Nasdaq listing criteria. We consider our Nasdaq listing an asset of the Company," said Lisa Conte, Jaguar's president and CEO.

The company reported net revenue increased 816% in the first quarter of 2026 compared to the first quarter of 2025, and increased 527% over the previous quarter. The revenue growth was attributed to a U.S. out-license agreement executed with Future Pak for Mytesi and Canalevia-CA1 in January 2026.

Jaguar stated it continues to focus on its development program for a proprietary powder-for-oral-solution formulation of crofelemer for rare intestinal failure indications, targeting a New Drug Application submission in mid-2027. The company is also seeking a development and commercialization partner for this program.

The information is based on a press release statement from Jaguar Health.